News

Novo: On Track To The Mid $40s While Loosing Market Share To Eli Lilly
Overall, Novo is expecting slower growth in 2025. The company is guiding for sales to rise between 16% and 24%, down from 26% ...
Fierce Pharma2d
Facing added pressure from Eli Lilly, Novo Nordisk submits for FDA approval of oral GLP-1 obesity drug
Nearly two years after reporting successful results from a phase 3 trial of its oral version of injected obesity treatment ...
The Hamilton Spectator16d
Novo Resources Corp. Unveils New Corporate Presentation for Investors
PERTH, Western Australia, April 09, 2025 (GLOBE NEWSWIRE) — Novo Resources Corp. (Novo or the Company) (ASX: NVO) (TSX: NVO) (OTCQB: NSRPF) is pleased to provide the launch of its April ...
Nasdaq16d
Novo Nordisk A/S (NVO) Is a Trending Stock: Facts to Know Before Betting on It
Shares of this drugmaker have returned -19.4% over the past month versus the Zacks S&P 500 composite's -12.2% change. The Zacks Large Cap Pharmaceuticals industry, to which Novo Nordisk belongs ...
KHOU 1126d
The Woodlands-based company strikes obesity-drug license deal worth up to $1B
THE WOODLANDS, Texas — A Houston-area pharmaceutical company has struck a billion-dollar deal with the seller of Ozempic for a potential drug also aiming to combat obesity. Lexicon ...